Poster Presentations

Lower non-response rates to 3-antigen HBV vaccine among adults with diabetes, age ≥ 45, or obesity compared to a single-antigen HBV vaccine: PROTECT STUDY

Conference: American Diabetes Association’s Virtual 81st Scientific Sessions
Date: June 25, 2021

Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study

Conference: Annual Meeting of the European Association for the Study of the Liver (EASL) 2021
Date: June 23, 2021

A 3-antigen prophylactic hepatitis B virus vaccine confers rapid onset of protection in young adults, age 18-45, compared to a single-antigen hepatitis B virus vaccine

Conference: Annual Meeting of the European Association for the Study of the Liver (EASL) 2021
Date: June 23, 2021

Robust Immunogenicity and Rapid Onset of High Rates of Seroprotection and Anti-HBs Titers, Elicited with 3-Antigen Hepatitis B Vaccine in Adults

Conference: 2021 International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)
Date: June 18, 2021

Evaluation of GM-CSF and AS01B Adjuvants in a Phase I/IIa Trial of a Therapeutic CMV Vaccine (VBI-1901) Against Recurrent Glioblastoma (GBM)

Conference: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Date: June 8, 2021

Higher seroprotection rates (SPR) and higher anti-HBs concentrations in adults age 18-45 immunized with 3-antigen hepatitis B vaccine (3A-HBV) compared to 1-antigen hepatitis B vaccine (1A-HBV): Results from the pivotal, double-blind, randomized Phase 3 study (CONSTANT)

Conference: Canadian Liver Meeting 2021
Date: May 5, 2021

Identification of a baseline biomarker associated with tumor responses in a Phase I/Iia trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Conference: 2020 Annual Meeting of the Society for Neuro-Oncology (SNO)
Date: November 19, 2020

A 3-antigen hepatitis B vaccine provides consistently higher seroprotection rates (SPR) and anti-HBs titers compared to single-antigen vaccine in adults with comorbidities known to be associated with poor response to vaccinations: Results from the phase III double-blind, randomized study (PROTECT)

Conference: American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2020
Date: November 13, 2020

Rapid onset of seroprotection rates in young adults immunized with a 3-antigen hepatitis B virus (HBV) vaccine compared to a single-antigen HBV vaccine

Conference: IDWeek 2020™
Date: October 26, 2020

Higher hepatitis B antibody titers induced in all adults vaccinated with a 3-antigen hepatitis B (HBV) vaccine, compared to a single-antigen HBV vaccine: Results from two pivotal phase 3 double-blind, randomized studies (PROTECT and CONSTANT)

Conference: IDWeek 2020™
Date: October 26, 2020

TCR and HLA analysis of patients in a Phase I/Iia trial of a therapeutic CMV vaccine against recurrent glioblastoma (rGBM)

Conference: The European Society for Medical Oncology (ESMO) Virtual Congress 2020
Date: September 17, 2020

Higher proportion of responders with hepatitis B antibody levels ≥ 100 mIU/mL with the tri-antigenic HepB vaccine, Sci-B-Vac®, compared to Engerix-B®: Results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)

Conference: The Digital International Liver Congress™ 2020 (ILC) - the Annual Meeting of the European Association for the Study of the Liver (EASL)
Date: August 31, 2020

CMV-specific immuno-dyregulation in recurrent glioblastoma patients can be overcome with therapeutic vaccineation which is associated with tumor response and overall survival benefits in a Phase I/Iia study

Conference: 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Date: June 22, 2020

Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Conference: 2019 Annual Meeting of the Society for Neuro-Oncology (SNO)
Date: November 22, 2019

Rapid increase in anti-HBsAg titers and higher seroprotection rates in adults immunized with Sci-B-Vac® compared to a monovalent hepatitis B vaccine: Results from PROTECT - a double-blind, randomized, controlled, Phase 3 study

Conference: American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2019
Date: October 22, 2019

CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against recurrent GBM

Conference: 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Date: June 4, 2019

High seroprotection rates achieved with two doses of Sci-B-Vac, a third-generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens

Conference: 2019 Annual Meeting of the European Association for the Study of the Liver (EASL)
Date: April 9, 2019

CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against recurrent GBM

Conference: 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
Date: October 24, 2018